Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Active, not recruiting · NCT03611738 · Registry updated 2026-05-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-05-15 | NCT03611738 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Advent Health Orlando | Orlando | United States | 10 |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | United States | 32 |